Table 5.
Variable | Adjusted HR | 95% CI | p-Value |
---|---|---|---|
Definitive 3GC Therapy a | 0.93 | 0.51–1.72 | 0.825 |
Adequate Empiric Therapy | 0.40 | 0.12–1.32 | 0.132 |
Male Sex | 0.67 | 0.42–1.08 | 0.097 |
CrCl, per mL/min increase | 1.00 | 0.99–1.08 | 0.223 |
Source of Infection other than Urinary Tract or CVC | 1.04 | 0.65–1.67 | 0.858 |
Site of Acquisition | |||
Community-Acquired | Ref. | - | - |
Healthcare-Associated | 0.85 | 0.46–1.57 | 0.596 |
Hospital-Acquired | 1.13 | 0.59–2.17 | 0.714 |
Malignancy | 1.71 | 0.98–2.99 | 0.059 |
Liver Cirrhosis | 1.88 | 0.80–4.46 | 0.151 |
Pitt Bacteremia Score, per point increase | 1.04 | 0.93–1.17 | 0.488 |
Penicillin/Cephalosporin Allergy | 1.30 | 0.80–2.13 | 0.292 |
Abbreviations: HR, hazard ratio; CI, confidence interval; 3GC, third-generation cephalosporin; CrCl, creatinine clearance; CVC, central venous catheter. a Definitive non-3GC therapy as the referent group.